These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33968542)

  • 1. Efficacy and Safety of Orally Administered Acotiamide Extended-Release Tablets Among Functional Dyspepsia-Postprandial Distress Syndrome Patients: A Randomized, Double-Blind, Multicenter Study.
    Sinha SD; Sinha SK; Talluri L; Bhashyakarla RK; Malladi U; Dosi RV; Jain MK; Chary S; Reddy M; Thakur P
    Cureus; 2021 Apr; 13(4):e14361. PubMed ID: 33968542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Acotiamide Versus Mosapride in Patients With Functional Dyspepsia Associated With Meal-Induced Postprandial Distress Syndrome: A Phase III Randomized Clinical Trial.
    Sinha S; Chary S; Thakur P; Talluri L; Reddy M; K GS; Mohan JM; Jain P; Naik S; C Reddy SV
    Cureus; 2021 Sep; 13(9):e18109. PubMed ID: 34692320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World, Non-Interventional, Observational Study to Evaluate Effectiveness and Tolerability of Acotiamide Hydrochloride Hydrate in Treatment of Functional Dyspepsia.
    Porika SK; Veligandla KC; Muni SK; Acharya S; Mehta SC; Sharma AD
    Adv Ther; 2018 Nov; 35(11):1884-1893. PubMed ID: 30350248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial.
    Tack J; Pokrotnieks J; Urbonas G; Banciu C; Yakusevich V; Bunganic I; Törnblom H; Kleban Y; Eavis P; Tsuchikawa M; Miyagawa T
    Neurogastroenterol Motil; 2018 Jun; 30(6):e13284. PubMed ID: 29315999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.
    Matsueda K; Hongo M; Tack J; Saito Y; Kato H
    Gut; 2012 Jun; 61(6):821-8. PubMed ID: 22157329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.
    Hojo M; Nagahara A; Asaoka D; Takeda T; Izumi K; Matsumoto K; Ueyama H; Shimada Y; Matsumoto K; Nojiri S; Watanabe S
    Digestion; 2017; 96(1):5-12. PubMed ID: 28605740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome.
    Altan E; Masaoka T; Farré R; Tack J
    Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):533-44. PubMed ID: 23061703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: systematic review and meta-analysis.
    Xiao G; Xie X; Fan J; Deng J; Tan S; Zhu Y; Guo Q; Wan C
    ScientificWorldJournal; 2014; 2014():541950. PubMed ID: 25197703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration.
    Matsueda K; Hongo M; Ushijima S; Akiho H
    Digestion; 2011; 84(4):261-8. PubMed ID: 21934307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zhizhu Kuanzhong Capsule in treating patients with functional dyspepsia postprandial distress syndrome: study protocol for a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial.
    Xiao M; Zhong LLD; Lam WC; Zhao Y; Gwee KA; Holtmann G; Tack J; Suzuki H; Chen MH; Xiao Y; Hou X; Liu J; Li Y; Tang XD; Lu F
    Trials; 2022 Jun; 23(1):454. PubMed ID: 35655286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan.
    Yamawaki H; Futagami S; Kawagoe T; Maruki Y; Hashimoto S; Nagoya H; Sato H; Kodaka Y; Gudis K; Akamizu T; Sakamoto C; Iwakiri K
    Neurogastroenterol Motil; 2016 Jul; 28(7):1037-47. PubMed ID: 26920949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
    Matsueda K; Hongo M; Tack J; Aoki H; Saito Y; Kato H
    Neurogastroenterol Motil; 2010 Jun; 22(6):618-e173. PubMed ID: 20059698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of functional dyspepsia in Chinese adult patients with domperidone: A multicenter, randomized, double-blind, placebo-controlled pilot study.
    Fang XC; Lin ZH; Wu YD; Tian A; Liu S; Wu DS; Lin H; Meng FD; Liu M; Du F; Shu HJ; Wang ZF; Zhuo JM; Wang P; Li MY; Xu J
    J Dig Dis; 2023 Nov; 24(11):603-610. PubMed ID: 37902019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kawarai Lefor A; Yamamoto H
    J Med Invest; 2016; 63(3-4):230-5. PubMed ID: 27644564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography.
    Kusunoki H; Haruma K; Manabe N; Imamura H; Kamada T; Shiotani A; Hata J; Sugioka H; Saito Y; Kato H; Tack J
    Neurogastroenterol Motil; 2012 Jun; 24(6):540-5, e250-1. PubMed ID: 22385472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia.
    Tack J; Janssen P
    Expert Opin Investig Drugs; 2011 May; 20(5):701-12. PubMed ID: 21417958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of acupuncture versus sham acupuncture for postprandial distress syndrome: study protocol for a randomized controlled trial.
    Hou YQ; Zhang X; Tu JF; Zheng Y; Yang JW; Kim M; Hu H; Wang LQ; Zhao JJ; Zhou W; Wang J; Zou X; Wang Y; Shi GX; Liu CZ
    Trials; 2019 Jan; 20(1):65. PubMed ID: 30658669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging therapeutic options for the management of functional dyspepsia.
    Vandenberghe A; Schol J; Van den Houte K; Masuy I; Carbone F; Tack J
    Expert Opin Pharmacother; 2020 Feb; 21(3):365-376. PubMed ID: 31899982
    [No Abstract]   [Full Text] [Related]  

  • 19. Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria.
    Vanheel H; Carbone F; Valvekens L; Simren M; Tornblom H; Vanuytsel T; Van Oudenhove L; Tack J
    Am J Gastroenterol; 2017 Jan; 112(1):132-140. PubMed ID: 27958284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia.
    Matsushita M; Masaoka T; Suzuki H
    Neurogastroenterol Motil; 2016 May; 28(5):631-8. PubMed ID: 26730749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.